Understanding the proposed rule
Plain-language explanations, carefully separated from claims we cannot verify.
What is tianeptine?
Tianeptine is a chemical compound that has been marketed and prescribed as a medication for depression in a number of countries outside the United States. No tianeptine product is approved by the FDA in the United States. In recent years, unapproved consumer products containing tianeptine have also been sold in the United States outside of any medical framework.
Whenever this site describes a scientific or medical claim beyond the text of the proposed rule, it will link to a source in the research library. Source entries that have not yet been verified are labeled "Source verification required."
How is prescription tianeptine different from unapproved retail products?
A prescription medicine in a national regulatory system has an approved formulation, an approved dose, labeling reviewed by a regulator, and a prescriber involved in the decision. An unapproved consumer product sold in a store has none of those safeguards: the amount of active ingredient may be inconsistent, the labeling may be inaccurate, and the health claims may be unsupported.
These are meaningfully different things. Much of the documented harm in the United States is associated with the second category. This campaign supports strong, enforceable action against that category.
What is DEA proposing?
On July 8, 2026, the Drug Enforcement Administration, Department of Justice published a notice of proposed rulemaking titled "Schedules of Controlled Substances: Placement of Tianeptine in Schedule I" (91 FR 42150; Federal Register Document 2026-13821; Docket DEA1596).
The proposal would permanently place tianeptine — including its specified isomers, esters, ethers, salts, and related salts — in Schedule I of the Controlled Substances Act. Public comments are due by 11:59 p.m. Eastern Time on August 7, 2026.
What does Schedule I mean?
Schedule I is the most restrictive category under the Controlled Substances Act. If finalized, Schedule I controls and sanctions would apply to activities including manufacture, distribution, import, export, research, chemical analysis, and possession.
Schedule I is not a sales restriction or a prescription requirement. It is the category applied to substances treated as having no currently accepted medical use in the United States.
Why does international prescription use matter?
The proposed rule itself acknowledges that tianeptine is approved as a prescription drug in European, Asian, and Latin American countries, typically for depression, while no tianeptine product is FDA-approved in the United States.
That does not automatically mean the substance should be available here. It does mean the agency should explain clearly how a substance prescribed under medical supervision elsewhere fits a category defined by the absence of accepted medical use.
Why do human clinical trials matter?
Human studies are the strongest evidence about how a substance behaves in people. Where human research exists, a scheduling decision should engage with it directly — describing which studies were considered, how they were weighted, and what conclusions follow.
Specific studies belong in the research library with full citations. This campaign does not summarize studies it has not verified.
What risks are real?
Tianeptine can be misused. High-dose use can be dangerous. Dependence and difficult withdrawal have been reported. Products sold with inaccurate labels or unsupported medical claims have caused serious harm.
This campaign does not dispute those risks and does not defend mislabeled products, unrestricted sales, misleading medical claims, or unsafe high-dose use.
What alternatives to Schedule I exist?
Options between an unregulated market and permanent Schedule I placement include targeted FDA enforcement against unapproved drug products, manufacturing and purity standards, accurate labeling requirements, age restrictions, quantity limits, prescription-only status, and placement in a less restrictive schedule.
A proportionate approach would address the documented product-level harms while preserving lawful medical and scientific research.
What happens after the comment period?
After comments close, the agency reviews the record and may finalize, modify, withdraw, or take further procedural steps on the proposal. Comments filed in the docket become part of the record the agency must consider.
This is why a specific, substantive comment matters more than a slogan — and why the campaign continues after August 7 through Congress and continued public education.
Read it yourself
The official proposed rule is the primary source for every fact on this page.